Simplified Chinese
The first municipal-level project in Daxing District to obtain the “Construction Preparation Letter” has been approved to commence construction, marking the Minhai Biotechnology New‑Type Vaccine International Industrial Base.
Release date:
2020-06-29
Author:
Source:
Abstract
On June 11, 2020, the first municipal‑level project in Beijing’s Daxing District to obtain a “Construction Preparation Letter” received approval to commence construction. According to a reporter from Company E, the project is the Minhai Biotechnology International Vaccine Industrial Base Construction Project, located within the Daxing District Biopharmaceutical Industry Base. Tianyancha data indicates that Minhai Biotechnology is a wholly owned subsidiary of the listed company Kangtai Biological (300601), a high‑tech enterprise specializing in the research, development, production, and sales of human vaccines.
It is reported that the Regulations of Beijing Municipality on Optimizing the Business Environment officially came into effect on April 28, 2020. The Regulations stipulate that, upon obtaining the Letter of Construction Readiness, projects may commence preliminary works such as earthmoving, slope stabilization, and dewatering, thereby effectively shortening the construction timeline and helping construction firms reduce project costs.
Currently, the construction team for Minhai Biologics’ international vaccine industrial base project has arrived on site and commenced work, with temporary facilities already rising from the ground. At the groundbreaking ceremony, Xiao Qiyou, Deputy General Manager of Minhai Biologics, stated: “Since the new Regulations came into effect, the Daxing District Housing and Urban–Rural Development Commission has provided substantial support to our project. They proactively coordinated with us, assisting in preparing documentation and facilitating communication and coordination, enabling the project to swiftly pass the municipal review for the Construction Preparation Letter and obtain that letter on June 1. This has allowed us to truly experience the policy advantages of the new Regulations.”
According to available information, the Minhai Biologics International Vaccine Industrial Base Project was designated as a key municipal project for 2020 by the Beijing Municipal People’s Government. The project covers a total area of 135 mu and includes a domestically leading R&D center for next-generation vaccines, as well as a state-of-the-art vaccine production base comprising 16 manufacturing facilities that comply with the latest GMP standards.
According to Kangtai Biological, the Minhai Biological New‑Type Vaccine Internationalization Industrial Base project holds significant importance not only for the company but also for the development of Beijing’s biopharmaceutical industry. The project is positioned as a public service platform for the biopharmaceutical sector, serving R&D institutions and manufacturing enterprises within the biopharmaceutical park; providing growth opportunities for domestic and international R&D organizations, technology‑driven enterprises, and overseas returnees; strengthening the industrial chain of the biopharmaceutical park, fostering an agglomeration of the biopharmaceutical industry, and establishing a comprehensive image of the sector as “world‑class internationally and domestically leading.”
The biopharmaceutical industry is a new engine of economic growth for Beijing and has become one of the city’s emerging industries with revenues exceeding 100 billion yuan. Through the implementation of the G20 Project, the sector has achieved large-scale development. Beijing boasts the largest number of research institutions in the biopharmaceutical field nationwide; however, R&D activities remain fragmented, making it difficult to pool resources and leverage synergies. There is thus a pressing need for an internationally‑level biopharmaceutical research institute to integrate resources and coordinate preclinical research.
Currently, the Daxing Biopharmaceutical Industry Base, serving as a demonstration zone centered on biopharmaceutical R&D and manufacturing and providing dedicated development space for Beijing’s biopharmaceutical sector, has become a key strategic front for the capital’s efforts to advance high-end pharmaceutical and healthcare manufacturing and technology‑driven services. The base has attracted national‑level regulatory testing and drug‑development institutions—including the China National Institute for Food and Drug Control, the Chinese Academy of Medical Sciences, and the China Academy of Traditional Chinese Medicine—alongside industry leaders such as Tong Ren Tang and Minhai Bio, thereby establishing a comprehensive industrial ecosystem spanning biologics, traditional Chinese medicine, innovative chemical drugs, medical devices, and the broader healthcare value chain, with total investments exceeding RMB 50 billion.
However, many small and medium-sized R&D enterprises lack the resources to fully meet the specific requirements of international pharmaceutical development and pilot-scale production, necessitating an international research platform to provide relevant services for the biopharmaceutical sector. Kangtai Biological believes that Minhai Biological’s new‑generation vaccine internationalization industrial base can enhance the brand value of Daxing District’s biopharmaceutical industry hub, “China Pharmaceutical Valley.”
On the demand side, in 2017, the global vaccine market was valued at US$27.7 billion, and it is projected to reach US$46.6 billion by 2024. In recent years, China’s vaccine market has experienced explosive growth, with the market size reaching RMB 35.4 billion in 2018—a 57.6% increase over 2017. According to Kangtai Biological, as the number of newborns declines and the population of middle-aged and elderly individuals expands, China’s vaccine consumption is expected to grow explosively in the years ahead.
Recommended Reading
Batch Release Status of the Company’s Products in 2026
2026-07-23
2026-07-15
2026-07-09
Contact Information
Customer Service Hotline
4001899806
Phone number
010-59613600
Official Website
Company Address
No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing
WeChat Official Account